PHUONG NGUYEN: Open Payments
NPI 1518387703 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,252 in 62 payments from 10 companies in 2025. Trend: 2023 $1,065 · 2024 $1,810 · 2025 $1,252
Food & beverage: $1,167Education: $85
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 14 | $337 |
| Madrigal Pharmaceuticals | 9 | $206 |
| ABBVIE INC. | 11 | $201 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $170 |
| Intercept Pharmaceuticals, Inc. | 8 | $138 |
| Ipsen Biopharmaceuticals, Inc | 3 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Mirum Pharmaceuticals, Inc. | 1 | $34 |
| Napo Pharmaceuticals Inc | 1 | $25 |
| PFIZER INC. | 1 | $19 |
Products named: TREMFYA, REZDIFFRA, XIFAXAN, OCALIVA, SKYRIZI, IQIRVO, MAVYRET, RINVOQ.
Industry payments across TX — which companies pay providers there.
